| Papers [1-15] of 100 :: [Page 1 of 7] | | Go to page : 1 2 3 4 5 6 7 —> | Search results on "PFIZER PHARMACEUTICAL COMPANY": |
|
|
Pfizer Pharmaceutical Company, 2004.
An analysis of the marketing success of the Pfizer Pharmaceutical Company.
1,938 words (approx. 7.8 pages), 6 sources, MLA, $ 61.95
»
Click here to show/hide summary
Abstract
This paper examines how Pfizer is one of the most successful pharmaceutical companies in existence and how much, if not most, of Pfizer?s success is due to the corporation?s marketing genius, which is considered to be among the best in the industry. It looks at how Pfizer also has one of the best safety records in the industry, which helps in gaining investors and trust in the company. It also explores how, unlike most large corporations, Pfizer draws revenue from a limited number of products.
Outline
Company Structure and Marketing Strategies
Marketing Strengths
Threats
From the Paper
"The marketing principles utilized by Pfizer guides every aspect of the corporation?s business. There are five main principles that are fundamental to Pfizer?s business practices. First, the work conducted by Pfizer is grounded in science. With solid clinical research as a foundation, Pfizer?s marketing group uses its credibility and knowledge to develop important relationships within the medical community. Second, Pfizer takes an integrated approach to its marketing strategies. Innovation is promoted through the encouragement of teamwork within and across marketing groups. This also allows Pfizer to respond flexibly and promptly to changes in the market."
| |
|
Pfizer, Inc. and the Pharmaceutical Industry, 2005.
This paper is a risk analysis of Pfizer, Inc. and the pharmaceutical industry including its direct competitors: Bayer AG, Merck & Co., Novartis AG, Abbott Labs and Eli Lilly.
2,175 words (approx. 8.7 pages), 7 sources, MLA, $ 67.95
»
Click here to show/hide summary
Abstract
This paper explains that Pfizer and all five of its direct competitors essentially face many of the same risks such as the tendency for the marketplace to discourage the use of new medicines because of their higher costs. The author points out that the safety of products and proper usage by consumers are always concerns as demonstrated by the problems facing Bayer and Merck and, now, potentially, by Pfizer with Celebrex. The paper concludes that Pfizer is unique from its competitors and remains the leading pharmaceutical company because of its effective risk and resource management of the company's extraordinary portfolio management practices, security of the day-to-day management of resources and its research and development.
From the Paper
"The third goal, corporate social responsibility, means putting people and communities first and preserving and protecting the environment. It also means being sensitive to the needs of Pfizer's colleagues, and evaluating the company from a critical point of view. Over the past four years, Pfizer has almost tripled in size, from about 45,000 colleagues worldwide to over 122,000. In 2003, Pfizer created a global corporate citizenship coordinating team. The goal of this group is to help unify Pfizer's approach to corporate citizenship across many countries and cultures, through membership in organizations that promote responsible business practices internationally. Some of the initiatives that have been explored are the reduction of carbon monoxide emissions and supplying global energy through cleaner sources. This final goal is a symbol of Pfizer's commitment to strengthen leadership and become more responsive."
| |
|
Pfizer Pharmaceuticals Inc, 2002.
This paper focuses on the mission and achievements of the pharmaceutical giant Pfizer.
2,400 words (approx. 9.6 pages), 5 sources, $ 89.95
»
Click here to show/hide summary
Abstract
This company has been present in the healthcare industry since 1849 and has given us some of the most well known drugs. Despite some weaknesses the company is poised to retain its status as one of the leading pharmaceutical firms in the 21st century too.
| |
|
Pfizer Inc., 2005.
A review of Pfizer Inc., one of the largest pharmaceutical companies in the USA.
675 words (approx. 2.7 pages), 0 sources, $ 26.95
»
Click here to show/hide summary
Abstract
This paper analyzes the US medical giant, Pfizer Inc. According to this paper, Pfizer Inc. is one of the leading pharmaceutical companies in the U.S. This paper reviews the company's place in the industry and their stock dividends.
From the Paper
"Pfizer is a U.S. based pharmaceutical company, which opened its doors 156 years ago in 1849 with a compound that was proven to take care of parasitic worms. There were two co-founders, Charles Pfizer and his cousin Charles Erhart. Both had come from Germany in the hopes of starting a business together. They had no idea that what they would leave behind would end up being one of the largest pharmaceutical companies in the nation ("Exploring our History", 2005). Industry Analysis Pfizer participates in an industry coded and named by the United States Department of Labor. As such they do business in Division D: Manufacturing - Major Group 28: Chemicals and Allied Products. Specifically Pharmaceutical Preparation coded 2834. Any company in this category produces, manufactures, "fabricates or processed pharmaceutical drugs in preparation for human or veterinary consumption" ("SIC Description for 2834", 2005)."
| |
|
Organizational Growth at Pfizer, 2008.
A discussion of the organizational growth of the Pfizer pharmaceutical company, through an analysis of the company's planning and marketing strategy.
1,605 words (approx. 6.4 pages), 6 sources, APA, $ 52.95
»
Click here to show/hide summary
Abstract
This paper takes a look at how the pharmaceutical company Pfizer has been quite effective at utilizing marketing strategy based market development to expand its revenue streams and extend the useful life of its existing products. The paper maintains that Pfizer's sales and marketing division is one of the drug industries best and has been a strong contributor to creating one of the most pathological advertising establishments in the United States. The paper uses the Ansoff matrix as a tool to assess Pfizer's marketing strategies in relation to the general drug market. The paper concludes that Pfizer owes its success to its vast resources, global distribution and channel technology, and brand equity.
Outline:
Introduction
Gap Analysis
Ansoff's Matrix-Strategic Planning
Recommended Solutions
Conclusion
From the Paper
"There are several strategies to accomplish growth. One of the easiest from an operational standpoint is to simply acquire or merge with another company which is inline with Ansoff's market or product development strategy. The exact nature of the strategy is dependent upon the character of the businesses being acquired or merged with. Mergers and acquisitions (M&A) provide companies with an instant expanded market and a new product or product line as well as, potentially, a completely new industry. If the M&A target is a company that focuses on a different market or market segment this would be a strategy based on market development because the primary company would be moving into what is, in effect, according to Ansoff, a new market."
| |
|
Pfizer, 2004.
This paper is a financial analysis of Pfizer, one of the largest pharmaceutical companies in the world.
1,310 words (approx. 5.2 pages), 2 sources, MLA, $ 44.95
»
Click here to show/hide summary
Abstract
This paper explains that Pfizer is in a very good financial situation as indicated in the Tables of Solvency and Profitability Measures. The author relates the working capital shows that the asset value is increasing at a greater pace than the liabilities; however, if the the current ratio in 2002 is compared to 2001, there is a slight decrease in its values, which shows us that the current liabilities have slightly increased in value. The paper states that the only possible problem could appear from the company?s tendency to finance its assets from long-term debt, but Pfizer has the power to support interest payment from its income.
From the Paper
"Net income has increased by 17 % from 2001 to 2002 and this may seem little if we look at the increase of net income from 2000 to 2001 (109 %!). If we analyze closer the Statement of Income, we will find out however that in 2000, income was low due to merger costs that accounted for $3,223 million, while in 2001 and 2002, these costs are negligible reported to earnings. Thus, we will report or findings by comparing the revenues from 2002 and 2001 and noting that the company has steadily increased its sales and net income, showing no downturn to recession."
| |
|
Pharmaceutical Public Relations, 2005.
This paper examines the public relations practices of three pharmaceutical companies: Merck and its product VIOXX, Pfizer and its product Celebrex and Johnson & Johnson and its Direct-to-the-Consumer (DTC) marketing campaign.
3,000 words (approx. 12.0 pages), 9 sources, APA, $ 88.95
»
Click here to show/hide summary
Abstract
This paper explains that companies often encounter ethical issues and product problems, which open them to criticism and challenge; therefore, the way they handle the issue can help or hinder their public relations process and the image the public has of the company. The author points out that, in general, companies, which take responsibility quickly and work to get out all the facts, fare better than those that stonewall, which for many executives seems to be their first action as in the case of both Merck and its product VIOXX, Pfizer and its product Celebrex. The paper praises Johnson & Johnson's Direct-to-the-Consumer (DTC) marketing campaign because it shows concern for what concerns its customers and offering the consumer information to be used in making decisions; however, the same danger applies if a problem erupts, but the strategy fits well with current public attitudes and with business methods that burnish a company's image.
From the Paper
"Critics of Pfizer note not only that the company may have had information on the dangers long before the issue was revealed and did nothing but that the company advertised in a way that minimized any risks and so lulled the public into accepting the safety of the product:
Several of the medical experts convened last month by the Food and Drug Administration to review Vioxx, Pfizer Inc.'s Celebrex and related painkillers lashed out against advertising that minimized the risks of the medicines and led many patients to use them unnecessarily."
| |
|
Pfizer, 2004.
A financial risk analysis of the worldwide pharmaceutical company, Pfizer.
1,599 words (approx. 6.4 pages), 5 sources, MLA, $ 52.95
»
Click here to show/hide summary
Abstract
This report examines and analyzes the company Pfizer in its position as a leading worldwide pharmaceutical company. The paper evaluates its risk position and total stock return in comparison to five of its direct competitors: Bayer AG, Merck & Co., Abbott Labs, Novartis and Eli Lilly. It also discusses the significance of Pfizer's partnerships with Pharmacia and Warner Lambert and the significance of these relationships on the company's overall financial performance.
From the Paper
"Pfizer is a research-based, global pharmaceutical company that discovers, develops, manufactures and markets leading prescription medicines for humans and animals, as well as many of the world's best known consumer healthcare products. Everything done at Pfizer is a reflection of the company's mission, a commitment to serving the total health-care continuum. Fine portfolio management practices help inform company executives, the day to day management of resources, allocation of employees, uncertainty in drug development and competitive pressures call for an unprecedented in-depth analysis monitoring the company's general risk exposure."
| |
|
Merck and Pfizer Inc., 2002.
A marketing analysis of the pharmaceutical companies Pfizer Inc. and Merck.
3,314 words (approx. 13.3 pages), 12 sources, MLA, $ 94.95
»
Click here to show/hide summary
Abstract
This paper provides an insight into the two pharmaceutical companies Pfizer Inc. and Merck with an emphasis on their marketing strategies. It outlines the companies? products, services and position in their industry and then provides a comparative analysis using the four Ps of marketing.
Outline
Introduction
Company Analysis - Pfizer Inc.
Line of Business and Sales and Profit Trends
The Specific Target Market(S) Sought
Company Brands, Manner of Distribution, Promotion Methods and Pricing
The Differential Advantages/Strengths of the Firm
International Performance
Company Analysis - Merck
Line of Business and Sales and Profit Trends
The Specific Target Market(S) Sought
Company Brands, Manner of Distribution, Promotion Methods and Pricing
The Differential Advantages/Strengths of the Firm
International Performance
Comparison
Web Sites
Describe Each Site
Strengths and Weaknesses of Each Site
Specific Sections
Improvement of Both the Sites
Conclusion
Bibliography
Appendix
From the Paper
"Unlike other firms, Pfizer's main business focus had been to improve its products and to extend its product line. Over the years, analysts find that Pfizer has spent much more on currency of its research and development as compared to business development and strategy. For example one analyst comments on Pfizer's strategy: "McKinnell is one of the primary architects of the acquisition strategy that has supercharged Pfizer's growth. So it's startling to hear him argue that the company's acquisition days are over. Despite the fact that Pfizer commands only 11% of the global pharmaceutical market, its growth, he declares, now lies in R&D, not M&A. "This Company?s future will be quite different," McKinnell says. "People tend to evaluate research looking out the back window, not the front. And the '90s were really unusual." [Simons, 2003]. For this reason it has leverage over other companies. However with the emergence of new prescription drugs and mandates in biomedical fields other companies like Merck, Pharmacia as well as Eli Lilly have been focusing their investments in these areas as well [See Appendix]. "
| |
|
The Pharmaceutical Industry, 2005.
This paper discusses the economics of the pharmaceutical industry.
3,130 words (approx. 12.5 pages), 7 sources, APA, $ 91.95
»
Click here to show/hide summary
Abstract
This paper explains that the intellectual property embodied in a drug is an extremely valuable asset for a pharmaceutical company, and its continued protection is directly related to the company's long-term success or failure. The author points out that Pfizer, the leading pharmaceutical company, has three main business practices and goals, which have overcome successfully the uncertainty in drug development and competitive pressures: (1) Extraordinary portfolio management practices, (2) security of daily management of resources and (3) profitable research and development. The paper relates that, in 1984 Congress passed of the Drug Price Competition and Patent Term Restoration Act, known as the Hatch-Waxman Act, which weakened patent law for pharmaceuticals making it easier for generic copies to enter the market.
Table of Contents
Intellectual Property
Risk and Resource Management
Drug Price Competition and Patent Term Restoration (Hatch-Waxman) Act
Food, Drug and Cosmetic Act
Amendments to the 1938 Food, Drug and Cosmetic Act
From the Paper
"As a result, a high average level of intellectual property protection is economically beneficial. The benefits of strong intellectual property protection are greater in the pharmaceutical industry than they are in other industries, because pharmaceutical firms rely more on patents to protect intellectual property than firms in other industries. When a drug becomes generic as the result of a lost patent, the price goes down, although the demand may remain the same. A less costly drug decreases profits for a pharmaceutical company, which in turn would use the additional profits to invest in their risk and development fund to search for new medicines and cures. Patent law gives pharmaceutical researchers the basic incentive to conduct research and discover new cures."
| |
|
Pfizer Drugs, 2005.
A look at the economics of the pharmaceutical industry, with a focus on the Pfizer Drug company.
1,431 words (approx. 5.7 pages), 5 sources, APA, $ 47.95
»
Click here to show/hide summary
Abstract
This paper describes the economic aspects of the pharmaceutical industry by focusing on the Pfizer Drug company. The paper examines the inelastic nature of pharmaceutical products, explains the oligopolistic nature of the pharmaceutical industry, looks at how pharmaceutical companies compete against one another, discusses the pricing of pharmaceutical products, and looks at what factors influence the business strategies of pharmaceutical companies.
From the Paper
"Although Pfizer?s claims to offer value to its consumers may be debatable, its contention that it is the leader of the industry in sheer dollar terms cannot be disputed. Of particular value to Pfizer as a stock has been its patent of the drug Viagra, and it continues to capitalize upon its dominance as an industry leader even in the second of its website that attempts to attract individuals to work for the company."
| |
|
Bristol Myers Squibb Company, 2008.
An in-depth marketing audit of the Bristol Myers Squibb Company (BMSC).
2,486 words (approx. 9.9 pages), 15 sources, APA, $ 75.95
»
Click here to show/hide summary
Abstract
The paper reveals that Bristol Myers Squibb Company's (BMSC) recent history can be summed up by its battle with Pfizer to gain control of the cardiovascular drug market. The paper provides an overview of Pfizer and offers a competitor profile matrix. The paper then discusses the industry rivalry and includes a SWOT analysis. The paper concludes that BMSC has developed a very integrated manufacturing and distribution network that has allowed it to capitalize on its brand image as a leading pharmaceutical company. The paper provides recommendations and includes an appendix detailing the company's background.
Outline:
The Competitive Environment
BMSC in the Marketplace
Conclusions & Recommendations
From the Paper
"The degree of industry rivalry in the pharmaceutical industry is high and potentially debilitating even for the larger competitors. Proctor identifies five levels of competition that most enterprises face in today's hyper-competitive marketplace: direct, close, similar products, substitute products and indirect competition (2000, p.103). These levels of competition vector with Porter's five forces model of competition whereby he models the relationship in the marketplace between competitive forces that together form a core of rivalry that is measured in degrees of intensity (Proctor, 2000). For the pharmaceutical industry, the degree of intensity in competitive forces is extremely high because the risks at stake are considerable; often in the 100s of millions to the billions."
| |
|
Pfizer's Marketing Strategy, 2008.
A research proposal about the marketing strategy of Pfizer, a major pharmaceutical industry competitor.
3,261 words (approx. 13.0 pages), 10 sources, APA, $ 93.95
»
Click here to show/hide summary
Abstract
This paper presents a proposal for a marketing strategy for the Pfizer pharmaceutical company that examines the competitive environment of the pharmaceutical industry within the context of Porter's five forces model and utilizes Merck as an illustrative competitor. The proposal explores whether Pfizer's marketing strategy is adequate for the present global environment and what possible strategic adjustments it could take to better position itself in the market. The proposal concludes with the inclusion of the academic base for the final research project.
Outline:
Background
Project Rationale
Reporting & Presentation
Timing
Proposal
From the Paper
"The need for the information related to this project arose because of the competitive nature of the pharmaceutical industry and Pfizer's need to remain market relevant. The organization and its executive management intend to leverage this information and data to result in a competitive advantage over the company's primary rivals in the industry. Although this research project focuses on a single company, Pfizer, and a primary competitor, Merck, its intent is to illustrate the importance and long-term necessity of developing evolutionary marketing strategies within a competitively restrictive environment."
| |
|
Pfizer Marketing Strategy, 2008.
A research proposal to discuss the marketing strategy of Pfizer, a major pharmaceutical industry competitor.
2,660 words (approx. 10.6 pages), 10 sources, APA, $ 79.95
»
Click here to show/hide summary
Abstract
The research examines the competitive environment of the pharmaceutical industry within the context of Porter's five forces model, utilizing Merck as an illustrative competitor. The paper discusses the problem statement that questions whether Pfizer's marketing strategy is adequate for the present global environment and what possible strategic adjustments it could take to better position itself in the market. The paper reveals the methodology to be used and concludes with the inclusion of the academic base for the final research project. The paper explains in an appendix why Pfizer is an excellent target enterprise for this research proposal.
Outline:
Executive Summary
Chapter 1: Background & Overview
Chapter 2: Research Objectives
Chapter 3: Methodology
Chapter 4: Presentation of Findings
Chapter 5: Conclusions & Recommendations
Proposed Time Schedule
From the Paper
"The pharmaceutical industry, as a sub-set of the medical and healthcare industry is highly competitive in nature. Additionally, it is a capital intensive industry relying heavily on research and development (R&D) without which its major competitors would not, and could not, bring new products to market. Yet, the marketing and distribution of these products is just as critical, if not more critical, than their development because programs must be developed to first create demand in the consumer market and then have the distribution network to deliver the products or products (Honeycutt, Ford & Simintiras, 2003, p.39)."
| |
|
Social Responsibility of Pharmaceutical Companies, 2004.
Study of the ethics of pharmaceutical companies when conducting business and promoting their products.
5,370 words (approx. 21.5 pages), 32 sources, MLA, $ 132.95
»
Click here to show/hide summary
Abstract
This paper addresses several questions concerning the ethical conduct of pharmaceutical companies. The paper considers whether doctors that sit on the boards of companies can be impartial when they make decisions to financially back research/drugs of the pharmaceutical company they represent, as well as what should be the corporate responsibility of the pharmaceutical companies. Also considered is whether pharmaceutical companies have systems in place to keep them ethically responsible and if advertising by pharmaceutical companies actually creates a demand for prescriptions when no need actually exists. Numerous graphs and tables are included.
From the Paper
"Indeed, one of the unique aspects of advertising prescription pharmaceuticals is the caveat ?Ask your doctor?. The consumer cannot go out and directly purchase the product (note that via the internet this is now possible), but traditionally must receive a physician?s endorsement by way of a prescription. The pharmaceutical industry uses this reasoning to defend its promotional tactics, claiming that because doctors ultimately authorize prescriptions the public is insulated from deceptive advertising. Yet research indicates that doctors are likely to prescribe drugs patients request under increasing pressure. Patients often insist on brand names over generic drugs, some of which are just as effective and less costly."
|
|
|
